Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

A drug approved to help slow the progression of Alzheimer’s is giving an Oklahoma couple hope. The drug is only for patients ...

American drugmaker Eli Lilly has said it will not restart paused investment in the UK until it sees changes to the types of ...

Anavex Life Sciences' Phase 2B/3 trial failed to achieve statistical significance on both primary endpoints. Read why I ...

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

Early Alzheimer's patients who completed their course of donanemab therapy by 12 months had cognitive and functional benefits lasting for 2 additional years, reported Jennifer Zimmer, MD, of Eli Lilly ...

Lilly’s efforts to more quickly deliver difference-making medicines to patients is just one example of the company’s approach ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

As researchers continue to advance the understanding of Alzheimer’s disease, new treatment options are offering hope for ...